Jump to content
Powered by

New production alliance in South West Germany

Rentschler Biotechnologie (Laupheim) and Boehringer Ingelheim (Biberach), a leading company in international biopharmaceutical contract development and production, have signed a preferred partnership agreement. The companies’ fermentation facilities are only a few kilometres away from each other. The agreement will allow even closer cooperation between the two companies.

Through this cooperation, clients of both companies will benefit from the combined development and manufacturing know-how and facilities: Rentschler Biotechnologie’s clients will gain access to Boehringer Ingelheim’s large-scale mammalian biopharmaceutical production facilities in Biberach, Germany and Boehringer Ingelheim’s clients will be able to use Rentschler’s facilities of process development and intermediate-scale clinical supply production. Compatible bioprocessing methods guarantee a seamless project transfer between the companies. The Laupheim-based company has recently announced the signing of a preferred partnership agreement with Boehringer Ingelheim.

From small- to large-scale production

Rentschler Biotechnologie currently owns eight independent GMP production plants with fermentation volumes of up to 500 litres. A new, 2,500-litre production plant is currently being brought into operation. The Upper Swabian neighbour of the company, Boehringer Ingelheim, offers similar services and technologies though in a larger scale. It operates one of the worldwide largest production plants with fermentation volumes of up to 15,000 litres.

Cooperation increases client benefit

According to Wieland Wolf, smooth process transfer increases the value for the clients. (Photo: Rentschler)
“The cooperation with Boehringer Ingelheim will increase the value of our services. Both companies will benefit from the combined expertise and the smooth transfer from small/medium to large-scale production,” commented Dr. Wieland Wolf, Vice Chairman of the Rentschler Group.

According to Professor Rolf Werner, Corporate Senior Vice President of the Corporate Division Biopharmaceuticals at Boehringer Ingelheim, the partnership “complements our worldwide strategic Production Alliance Network” and combines state-of-the-art development at Rentschler for accelerated time to clinic with a smooth technology transfer to Boehringer Ingelheim for large-scale commercial manufacturing.

Source: Rentschler Biotechnologie, 21.05.08 (P, wp, 26.05.08)
Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-production-alliance-in-south-west-germany